Patent intelligence · US
US 9314456
Antibacterial compounds
Antibacterial compounds
Patent details — US 9314456
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 19, 2016
- Expiration
- Apr 14, 2036
- Applicant
- SUMMIT THERAPEUTICS PLC
- Claims
- 3
- CPC classes
- A61K, A61K31/4439, A61K31/444, A61P
Quick answer
US 9314456 (Antibacterial compounds) is held by SUMMIT THERAPEUTICS PLC. Status: granted. Granted Apr 19, 2016. Expires Apr 14, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUMMIT THERAPEUTICS PLC
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K31/4439, A61K31/444, A61P, A61P1/04, A61P1/12
More from SUMMIT THERAPEUTICS PLC
Related pharmaceutical patents in our USPTO index.
-
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 11344575
Vascular calcification prevention and treatment
granted -
US 11007171
Treatment and prevention of joint disorders
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Frequently asked questions
What is US patent 9314456?
US 9314456 (Antibacterial compounds) is held by SUMMIT THERAPEUTICS PLC. Status: granted. Granted Apr 19, 2016. Expires Apr 14, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9314456?
SUMMIT THERAPEUTICS PLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 9314456 expire?
Our index shows an expiration date of Apr 14, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.